- Home
- NVNO vs OTLK Comparison
NVNO vs OTLK Comparison
Compare NVNO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- OTLK
- Stock Information
- Founded
- NVNO 1987
- OTLK 2010
- Country
- NVNO United States
- OTLK United States
- Employees
- NVNO N/A
- OTLK N/A
- Industry
- NVNO Medical/Dental Instruments
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVNO Health Care
- OTLK Health Care
- Exchange
- NVNO Nasdaq
- OTLK Nasdaq
- Market Cap
- NVNO 41.0M
- OTLK 48.3M
- IPO Year
- NVNO N/A
- OTLK 2016
- Fundamental
- Price
- NVNO $3.65
- OTLK $1.53
- Analyst Decision
- NVNO
- OTLK Strong Buy
- Analyst Count
- NVNO 0
- OTLK 5
- Target Price
- NVNO N/A
- OTLK $10.20
- AVG Volume (30 Days)
- NVNO 76.7K
- OTLK 274.9K
- Earning Date
- NVNO 05-01-2025
- OTLK 05-19-2025
- Dividend Yield
- NVNO N/A
- OTLK N/A
- EPS Growth
- NVNO N/A
- OTLK N/A
- EPS
- NVNO N/A
- OTLK N/A
- Revenue
- NVNO N/A
- OTLK N/A
- Revenue This Year
- NVNO N/A
- OTLK N/A
- Revenue Next Year
- NVNO $409.09
- OTLK $288.46
- P/E Ratio
- NVNO N/A
- OTLK N/A
- Revenue Growth
- NVNO N/A
- OTLK N/A
- 52 Week Low
- NVNO $2.03
- OTLK $0.87
- 52 Week High
- NVNO $6.48
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- NVNO 71.64
- OTLK 55.94
- Support Level
- NVNO $2.61
- OTLK $1.35
- Resistance Level
- NVNO $3.97
- OTLK $1.62
- Average True Range (ATR)
- NVNO 0.22
- OTLK 0.10
- MACD
- NVNO 0.11
- OTLK -0.00
- Stochastic Oscillator
- NVNO 80.00
- OTLK 54.55
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.